Kit Products (Ex-US)

Our ultra-sensitive OncoBEAMTM and Plasma-SeqSensei Kit products are developed to provide reliable molecular information for timely and non-invasive treatment selection, molecular monitoring and enhanced prediction of resistance to therapy. Depending on the clinical issue, clinicians can choose between different available Kits based on the highly sensitive technologies BEAMing (digital PCR) or SafeSEQ (NGS), which can be run on-site in clinically validated Laboratories. For analysis only a simple blood draw is needed.

 

OncoBEAMTM Kits

Our digital PCR-based OncoBEAMTM Kits can be used to identify and select patients, which are suitable for cancer-specific therapy. Different Kits for Lung cancer and Coloractal cancer are available.

Plasma-SeqSensei Kits

Plasma-SeqSensei Kits are NGS liquid biopsy solutions designed to detect genomic alterations and characterized hotspot regions responsible for clinically relevant targets.

 

The OncoBEAM EGFR kit v2 enables the detection of EGFR mutations which play an essential role for therapy selection in non-small cell lung cancer (NSCLC).

Sysmex Inostics‘ highly sensitive OncoBEAM RAS CRC & BRAF kits use the non-invasive liquid biopsy mutation detection technology to analyze the cell-free circulating Tumor DNA which enables to select CRC patients eligible for anti-EGFR therapy.

The highly sensitive detection capacity of our Plasma-SeqSensei RUO Kits will allow for identification of clinically-relevant mutations for breast cancer, colorectal cancer, NSCLC, AML and head and neck cancer.